Bergamino M, et al. - The prognostic value of fasting plasma glucose (FPG) and diabetes mellitus was investigated among 170 patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy from 2010 to 2014. Patients with FPG ≥7 mmol/L had median PFS of 8.0 months and median overall survival (OS) of 15.0 months at a median follow-up of 36 months, compared to 20 months and 31 months, respectively, for patients with FPG < 7 mmol/L. This suggests an independent predictive value of baseline FPG level for survival in this cohort of patients with locally advanced NSCLC treated with concurrent chemoradiotherapy.